InvestorsHub Logo
Followers 53
Posts 1776
Boards Moderated 0
Alias Born 03/22/2015

Re: None

Thursday, 02/10/2022 11:43:30 AM

Thursday, February 10, 2022 11:43:30 AM

Post# of 401684
Submitted


Question for CC:

During the last several calls, the CEO has discussed using "our technology" for an ADF version of CNS stimulants. He said our technology is effective on all pleasure centers and "even works on alcohol", which suggests he is referring to naltrexone drug effects. Is the CEO considering the development of a naltrexone-based antagonist ADF for CNS stimulants? If so, what is the evidence that naltrexone can be used as an antagonist molecule for CNS stimulants? Are there are any studies that can be cited that suggest this would be effective? Are there any other drugs or experimental molecules that he is aware of that have shown this to be possible? What are they?




#FreeSequestOx


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News